AFMD News and Press, Affimed N.V. From 04/08/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

The recommended phase 2 dose was determined at 480 mg AFM24 has demonstrated a well-managed safety profile Pharmacodynamic activity was observed at doses of 160 mg and higher The maximum tolerated dose was not reached and the dose escalation continues at 720 mg For the b...

Affimed N.V. (AFMD) Q4 2021 Earnings Conference Call March 31, 2022, 8:30 AM ET Company Participants Adi Hoess – Chief Executive Officer Angus Smith – Chief Financial Officer Alex Fudukidis – Head of Investor Relations Andreas Harstrick – Chief Medical Officer Arnd...

Affimed press release (NASDAQ:AFMD): FY GAAP EPS of -€0.48. Revenue of €40.37M (+42.3% Y/Y). CEO comment: “We spent a good portion of 2021 transforming our organization by growing our team of dedicated scientists and industry experts. This investment in acquiring the...

Completed enrollment for AFM13-202 monotherapy study, REDIRECT, and on track to report topline data in the second half of 2022 Presented interim data in December 2021 of the combination study of AFM13 with NK cells (AFM13-104), showing 100% ORR after one treatment cycle at the highest...

Affimed (NASDAQ:AFMD) is scheduled to announce FY earnings results on Thursday, March 31st, before market open. The consensus EPS Estimate is -$0.54 (-8.0% Y/Y) and the consensus Revenue Estimate is $42.01M (+47.9% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1...

ACTG, AFMD, OTCPK:BRPHF, OTCQX:CBWTF, CLSN, GOED, LTRY, NNDM, NNOX, PDSB, PLX, PTR, TRVN, WBA For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open

HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2021 results and corporate update on Thursday,...

In a Clinical Trials Plenary Session an update of the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13 in patients with CD30-positive lymphomas will be presented A poster on the dose-escalation phase of the clinical t...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...